Given the involvement of CFAP418 in BBS pathogenesis (9, 12, 13), we performed semiquantitative immunoblot analysis for BBS2, BBS4, and ARL13B, for which commercial antibodies are available. The gene discussed is BBS2; the disease is Bardet-Biedl syndrome.